Yahoo
NYSE - Nasdaq Real Time Price USD

Accendra Health, Inc. (ACH)

0.2542 +0.0212 (+9.10%)
At close: 4:00:02 PM EDT
0.2599 +0.0057 (+2.24%)
After hours: 6:39:56 PM EDT
Trade ACH on Coinbase
Chart Range Bar
Loading chart for ACH
  • Previous Close 0.2330
  • Open 0.2299
  • Bid 0.2477 x 20000
  • Ask 0.2479 x 100000
  • Day's Range 0.2300 - 0.2542
  • 52 Week Range 0.1900 - 5.1200
  • Volume 1,548,111
  • Avg. Volume 1,872,607
  • Market Cap (intraday) 19.549M
  • Beta (5Y Monthly) 1.57
  • PE Ratio (TTM) --
  • EPS (TTM) -1.4400
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 1.26
  • Motley Fool Rating Bearish

Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services. The company also supplies other home medical equipment, patient care product lines including ostomy, wound care and negative pressure wound therapy, urology, incontinence, and other products and services. It serves patients and home health agencies. The company was formerly known as Owens & Minor, Inc. and changed its name to Accendra Health, Inc. in December 2025. Accendra Health, Inc. was founded in 1882 and is based in Glen Allen, Virginia.

www.accendrahealth.com

6,500

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ACH
90.92%
S&P 500 (^GSPC)
10.73%

1-Year Return

ACH
94.88%
S&P 500 (^GSPC)
11.11%

3-Year Return

ACH
98.18%
S&P 500 (^GSPC)
81.91%

5-Year Return

ACH
99.29%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 613.23M
Earnings --
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
200M
400M
600M
-6.0%
-4.0%
-2.0%
0.0%

Analyst Insights

View More

Analyst Price Targets

0.50
1.26 Average
0.2542 Current
1.75 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/13/2026
Analyst UBS
Rating Action Maintains
Rating Neutral
Price Action Lowers
Price Target 4.5 -> 1.5

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -11.41%

  • Return on Assets (ttm)

    0.64%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    2.65B

  • Net Income Avi to Common (ttm)

    -110.59M

  • Diluted EPS (ttm)

    -1.4400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.65M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    420.23M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: